After graduating from the University
of Toronto, Faculty of Medicine in 1992, Dr. Mark Silverberg completed
his internal medicine and gastroenterology training in Toronto in 1997.
He then obtained a PhD studying the genetics of inflammatory bowel
disease in 2002 at the Samuel Lunenfeld Research Institute of Mount
Sinai Hospital. He is currently a Professor and Clinician Scientist in
the Department of Medicine and holds the Gale and Graham Wright
Research Chair in Digestive Diseases. He runs a laboratory based at
Mount Sinai Hospital and the Lunenfeld-Tanenbaum Research Institute
investigating the causes of inflammatory bowel disease
His research program has been funded by grants from the National
Institute of Diabetes and Digestive and Kidney Diseases (NIDDK/NIH),
Canadian Institutes of Health Research (CIHR), Crohn's and Colitis
Canada (CCC) and the Crohn's and Colitis Foundation of America (CCFA).
His laboratory has focused on identifying susceptibility genes for IBD
and to explain the contribution of genes and other biomarkers to its
etiology and clinical course.
More recently he has expanded his program to study the relationship
between serum immune responses, gene regulation and the host microbiome
with genetic susceptibility. He has made significant contributions to
the discovery of genes related to Crohn's disease, ulcerative colitis
and paediatric IBD. He also has made major contributions to clinical
IBD research in the field of phenomics, classification of IBD (The
Montreal Classification) and as well as in optimal use of biologic
therapy and therapeutic drug monitoring.
Dr. Silverberg has taken leadership positions on several
international collaborative efforts with the goal of expediting
scientific progress in the field of IBD. These include the
International IBD Genetics Consortium, the NIDDK IBD Genetics
Consortium and the CCFA Microbiome Initiative. Dr. Silverberg is also
currently the Director of the Advanced IBD Fellowship Program at MSH
and co-director of the Canadian GI Fellows Program in IBD.
His current projects are directed toward understanding the
relationship between the microbiome in the digestive tract and host
genotype allowing more insight into the role of diet and how food may
trigger or exacerbate IBD. Ultimately he hopes to develop tools that
will allow clinicians to better predict who may develop IBD and to
identify high-risk patients so that a more personalized approach to
treatment based on patients' unique genetic and bacterial signatures
may be employed. Dr. Silverberg also runs a large clinical practice
focused on IBD at Mount Sinai Hospital.